The FDA will make a decision whether or not to grant full approval of Sarepta’s gene therapy, Elevidys, by June 21,2024.
Fat embolism syndrome (FES) is a potentially life-threatening condition that can be triggered by bone fractures.
CureDuchenne and the Finazzo family of Miami will host “Champions in Miami” on Saturday, March 9, 2024 at the Kimpton Surfcomber in Miami Beach, bringing together Miami’s top business leaders, entrepreneurs, influencers, and philanthropists for a night of delicious flavors, cocktails, cigars, and live entertainment. All event proceeds will benefit CureDuchenne, a global leader in research, patient care, and innovation for improving and extending the lives of those living with Duchenne muscular dystrophy.
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
Sarepta Therapeutics reported positive data for SRP-5051, their next-generation exon skipping agent designed for individuals amenable to skipping Exon 51. In part B of the Phase 2 MOMENTURM study, ambulatory and […]
Join PTC Therapeutics and CureDuchenne for this prerecorded webinar to hear important information regarding Emflaza, PTC Cares and the programs that support the Duchenne community. Topics include:Understanding Your PrescriptionHow to Ensure Your Son […]
CureDuchenne Welcomes Patricia Brown as Senior Director of Community Engagement
CureDuchenne Announces Educational Events for Families and Caregivers of Individuals with Duchenne or Becker Muscular Dystrophy
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for DMD in the UK.
